(Total Views: 807)
Posted On: 09/27/2020 9:53:34 AM
Post# of 155790
Oncoimmune: -OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020. This is a Phase 1A/1B trial
(0)
(0)
